<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Suven Life Sciences Limited — News on 6ix</title>
<link>https://6ix.com/company/suven-life-sciences-limited</link>
<description>Latest news and press releases for Suven Life Sciences Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 11 Dec 2025 15:14:45 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/suven-life-sciences-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68364f8e78dffbe2df154f71.webp</url>
<title>Suven Life Sciences Limited</title>
<link>https://6ix.com/company/suven-life-sciences-limited</link>
</image>
<item>
<title>Press Release Dec 11 2025</title>
<link>https://6ix.com/company/suven-life-sciences-limited/news/press-release-dec-11-2025-23</link>
<guid isPermaLink="true">https://6ix.com/company/suven-life-sciences-limited/news/press-release-dec-11-2025-23</guid>
<pubDate>Thu, 11 Dec 2025 15:14:45 GMT</pubDate>
<description>Suven Life Sciences Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "Suven Life Sciences achieved 100% Patient Enrolment Milestone in Phase-2b Clinical Trial of Ropanicant for Major Depressive Disorder (MDD), more than Two Months Ahead of Schedule".</description>
</item>
<item>
<title>Press Release Aug 13 2025</title>
<link>https://6ix.com/company/suven-life-sciences-limited/news/press-release-aug-13-2025-70</link>
<guid isPermaLink="true">https://6ix.com/company/suven-life-sciences-limited/news/press-release-aug-13-2025-70</guid>
<pubDate>Wed, 13 Aug 2025 19:01:43 GMT</pubDate>
<description>Suven Life Sciences Limited has informed the Exchange regarding a press release dated August 13, 2025, titled "News Release".</description>
</item>
<item>
<title>Press Release Jul 16 2025</title>
<link>https://6ix.com/company/suven-life-sciences-limited/news/press-release-jul-16-2025-24</link>
<guid isPermaLink="true">https://6ix.com/company/suven-life-sciences-limited/news/press-release-jul-16-2025-24</guid>
<pubDate>Wed, 16 Jul 2025 16:50:44 GMT</pubDate>
<description>Suven Life Sciences Limited has informed the Exchange regarding a press release dated July 16, 2025, titled "Suven Life Sciences announces First Patient Randomized in Phase-2b Clinical Trial of Ropanicant, an &#945;4&#946;2 Antagonist representing a Novel Mechanism of Action for the treatment of Major Depressive Disorder".</description>
</item>
<item>
<title>Press Release Jan 08 2025</title>
<link>https://6ix.com/company/suven-life-sciences-limited/news/press-release-jan-08-2025-18</link>
<guid isPermaLink="true">https://6ix.com/company/suven-life-sciences-limited/news/press-release-jan-08-2025-18</guid>
<pubDate>Wed, 08 Jan 2025 18:21:51 GMT</pubDate>
<description>Suven Life Sciences Limited has informed the Exchange regarding a press release dated January 08, 2025, titled "Suven Life Sciences Announces First Subjects Dosed in Phase-1 Clinical Trial of SUVN-I6107, a True Muscarinic M1 Positive Allosteric Modulator (M1 PAM) for the Treatment of Cognitive Disorders".</description>
</item>
<item>
<title>Press Release Sep 18 2024</title>
<link>https://6ix.com/company/suven-life-sciences-limited/news/press-release-sep-18-2024-14</link>
<guid isPermaLink="true">https://6ix.com/company/suven-life-sciences-limited/news/press-release-sep-18-2024-14</guid>
<pubDate>Wed, 18 Sep 2024 15:51:40 GMT</pubDate>
<description>Suven Life Sciences Limited has informed the Exchange regarding a press release dated September 18, 2024, titled "Suven Life Sciences Announces Positive Topline Results from Phase-2a Proof-of-Concept Signal Detection Open Label Study of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder (MDD)".</description>
</item>
<item>
<title>Press Release Aug 27 2024</title>
<link>https://6ix.com/company/suven-life-sciences-limited/news/press-release-aug-27-2024-17</link>
<guid isPermaLink="true">https://6ix.com/company/suven-life-sciences-limited/news/press-release-aug-27-2024-17</guid>
<pubDate>Tue, 27 Aug 2024 18:55:26 GMT</pubDate>
<description>Suven Life Sciences Limited has informed the Exchange regarding a press release dated August 27, 2024, titled "Suven Life Sciences Announces FDA acceptance of Investigational New Drug (IND) and grant of Study may proceed Letter to initiate Phase-1 Clinical Trial of SUVN-I6107, a True Muscarinic M1 Receptor Positive Allosteric Modulator (M1-PAM)".</description>
</item>
<item>
<title>Press Release May 06 2024</title>
<link>https://6ix.com/company/suven-life-sciences-limited/news/press-release-may-06-2024-26</link>
<guid isPermaLink="true">https://6ix.com/company/suven-life-sciences-limited/news/press-release-may-06-2024-26</guid>
<pubDate>Mon, 06 May 2024 23:06:23 GMT</pubDate>
<description>Suven Life Sciences Limited has informed the Exchange regarding a press release dated May 06, 2024, titled "News Release".</description>
</item>
<item>
<title>Press Release Apr 15 2024</title>
<link>https://6ix.com/company/suven-life-sciences-limited/news/press-release-apr-15-2024-16</link>
<guid isPermaLink="true">https://6ix.com/company/suven-life-sciences-limited/news/press-release-apr-15-2024-16</guid>
<pubDate>Mon, 15 Apr 2024 15:19:42 GMT</pubDate>
<description>Suven Life Sciences Limited has informed the Exchange regarding a press release dated April 15, 2024, titled "Suven Life Sciences to present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology (AAN) 2024 Annual Meeting, Denver, USA".</description>
</item>
<item>
<title>Press Release Feb 06 2024</title>
<link>https://6ix.com/company/suven-life-sciences-limited/news/press-release-feb-06-2024-48</link>
<guid isPermaLink="true">https://6ix.com/company/suven-life-sciences-limited/news/press-release-feb-06-2024-48</guid>
<pubDate>Tue, 06 Feb 2024 16:15:06 GMT</pubDate>
<description>Suven Life Sciences Limited has informed the Exchange regarding a press release dated February 06, 2024, titled "Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder study in USA".</description>
</item>
<item>
<title>Press Release Oct 30 2023</title>
<link>https://6ix.com/company/suven-life-sciences-limited/news/press-release-oct-30-2023-45</link>
<guid isPermaLink="true">https://6ix.com/company/suven-life-sciences-limited/news/press-release-oct-30-2023-45</guid>
<pubDate>Mon, 30 Oct 2023 18:35:45 GMT</pubDate>
<description>Suven Life Sciences Limited has informed the Exchange regarding a press release dated October 30, 2023, titled "Suven Life Sciences announces Positive Topline Results from a Phase-2 study evaluating Samelisant (SUVN-G3031) for Excessive Daytime Sleepiness (EDS) in adult Narcolepsy patients with and without cataplexy".</description>
</item>
<item>
<title>Press Release Jun 01 2023</title>
<link>https://6ix.com/company/suven-life-sciences-limited/news/press-release-jun-01-2023-18</link>
<guid isPermaLink="true">https://6ix.com/company/suven-life-sciences-limited/news/press-release-jun-01-2023-18</guid>
<pubDate>Thu, 01 Jun 2023 16:51:50 GMT</pubDate>
<description>Suven Life Sciences Limited has informed the Exchange regarding a press release dated Jun 01, 2023, titled "Suven Life Sciences completed enrollment of patients to the phase-2, Proof of Concept (PoC) clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada".</description>
</item>
<item>
<title>Press Release Nov 16 2022</title>
<link>https://6ix.com/company/suven-life-sciences-limited/news/press-release-nov-16-2022-22</link>
<guid isPermaLink="true">https://6ix.com/company/suven-life-sciences-limited/news/press-release-nov-16-2022-22</guid>
<pubDate>Wed, 16 Nov 2022 22:30:35 GMT</pubDate>
<description>Suven Life Sciences Limited has informed the Exchange about press release dated 16-Nov-2022 titled Suven Life Sciences Limited Announces Randomization of First Patient in Phase-3 Global Clinical Trial of Masupirdine (SUVN-502) for the Treatment of Agitation in Patients with Dementia of the Alzheime</description>
</item>
<item>
<title>Press Release Aug 16 2021</title>
<link>https://6ix.com/company/suven-life-sciences-limited/news/press-release-aug-16-2021-24</link>
<guid isPermaLink="true">https://6ix.com/company/suven-life-sciences-limited/news/press-release-aug-16-2021-24</guid>
<pubDate>Mon, 16 Aug 2021 20:11:21 GMT</pubDate>
<description>Suven Life Sciences Limited has informed the Exchange regarding a press release dated August 16, 2021, titled "Suven Life sciences announces Phase 3 Clinical Trial of SUVN-502 (Masupirdine), a 5-HT6 antagonist for treatment of Agitation and aggression in Alzheimer s type dementias".</description>
</item>
<item>
<title>Press Release Aug 26 2020</title>
<link>https://6ix.com/company/suven-life-sciences-limited/news/press-release-aug-26-2020-8</link>
<guid isPermaLink="true">https://6ix.com/company/suven-life-sciences-limited/news/press-release-aug-26-2020-8</guid>
<pubDate>Wed, 26 Aug 2020 22:05:26 GMT</pubDate>
<description>Suven Life Sciences Limited has informed the Exchange regarding a press release dated August 26, 2020, titled "Suven Life Sciences announces five poster presentations including Phase-2 proof-of-concept study design for SUVN-G3031 in patients with narcolepsy at the SLEEP 2020 virtual conference".</description>
</item>
<item>
<title>Press Release (Revised) Aug 11 2020</title>
<link>https://6ix.com/company/suven-life-sciences-limited/news/press-release-revised-aug-11-2020-3</link>
<guid isPermaLink="true">https://6ix.com/company/suven-life-sciences-limited/news/press-release-revised-aug-11-2020-3</guid>
<pubDate>Tue, 11 Aug 2020 20:39:53 GMT</pubDate>
<description>Suven Life Sciences Limited has informed the Exchange regarding a revised press release dated August 11, 2020, titled "SUVEN Life Sciences Limited ("Suven", "Company") today announced unauditedfinancial results for the quarter ended 30th June 2020".</description>
</item>
</channel>
</rss>